<DOC>
	<DOC>NCT01359228</DOC>
	<brief_summary>The purpose of this study is to determine the effects of rifaximin on skin symptoms in patients with rosacea by double-blinded, placebo-controlled, crossover study.</brief_summary>
	<brief_title>Rifaximin Treatment of Papulopustular Rosacea</brief_title>
	<detailed_description>100 patients will be randomized into two groups. Group A will receive one rifaximin 550 mg tablet three times a day (1650 mg/day) for 14 days, and after a 4-week washout period, receive one placebo tablet three times a day for 14 days. Group B will receive placebo first, and then rifaximin with the same dosage schedule to Group A. Assessments will be performed before application and 4 weeks after the last dosage, for both of rifaximin and placebo.</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Males and females &gt; 18 years of age with rosacea defined as: 340 papules/pustules and &lt; 2 nodules, A score of 24 on the Investigator Global Assessment Untreated pancreatic insufficiency Crohn's disease Ulcerative colitis Active celiac disease by clinical history End stage renal failure Less than 18 years old Pregnancy or positive pregnancy test Rosacea subtype 1 (no papules ) Topical or oral antibiotics within 4 weeks Acne treatments within 4 weeks prior to randomization Systemic retinoids within 90 days Topical or systemic corticosteroids 4 weeks prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Rosacea</keyword>
</DOC>